Evidence map›Paper›PMID 39595555›Full record

ArticleBiomolecules2024

The Functional Impact of VX-770 on the Cystic Fibrosis Transmembrane Conductance Regulator Is Enduring and Increases the Constitutive Activity of This Channel in Primary Airway Epithelia Generated from Healthy Donors.

Heidi J Nick, Sarah E Christeson, Preston E Bratcher

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Heidi J NickDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.
Sarah E ChristesonDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.
Preston E BratcherDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.ORCID 0000-0003-2240-8632

Funding

Contribution of pulmonary ionocytes and neuroendocrine cells to ion transport-mediated airway surface liquid maintenanceR01HL155325 · NHLBI · NATIONAL JEWISH HEALTH · PI BRATCHER, PRESTON E · 2021 to 2025
$2.3M
Cystic Fibrosis Foundation BRATCH21I0NHLBI NIH HHS R01 HL155325NIH HHS 1R01HL155325-04A1
6 · The paper itself

Abstract

VX-770 is a small-molecule CFTR potentiator that is highly efficacious in individuals with cystic fibrosis caused by mutations in CFTR that result in a defect in channel gating. While studies have reported on the mechanism of action of VX-770, there is still more to learn about the impact that it has on CFTR function in various contexts. The aim of the present study was to examine the longevity and stability of the effect of VX-770 on CFTR function in cultured airway epithelia and to measure the consequences of this interaction. The responses to acute and chronic VX-770 exposure were measured in cultures of expanded and re-differentiated primary human nasal epithelial cells. Acute VX-770 exposure resulted in an increase in CFTR-mediated currents in the absence of exogenous compounds that induce the phosphorylation/activation of CFTR, with acute exposure having the same effect as chronic exposure. The functional impact of VX-770 on CFTR was long-lasting in cultured airway epithelia, as they maintained an electrophysiological profile consistent with the saturation of CFTR with VX-770 over time periods of up to 4 days following a short (0.5 min) or low-dose (100 nM) exposure to VX-770 during an analysis in an Ussing chamber. Rinsing the apical surface prior to VX-770 exposure or exposure during the analysis in the Ussing chamber increased the interaction between VX-770 and the CFTR. Importantly, after short, low-dose exposures to VX-770, the CFTR channels in cultured epithelia appeared to remain saturated with VX-770 for extended periods of time, despite the repetitive rinsing of the apical surface. This finding has implications for patients discontinuing the use of VX-770-containing therapies.

Indexed as

AminophenolsCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesCells, CulturedCystic FibrosisEpithelial CellsHumansNasal MucosaAminophenolsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolonesairway ion transportCFTRCFTR potentiatorcystic fibrosisivacaftorVX-770

Identifiers

PMID39595555
PMCPMC11591604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.